[Featured Stock] Kolon TissueGene's Osteoarthritis Treatment Valued at 5 to 12 Trillion Won... Target Price 100,000 Won

Kolon TissueGene is showing strong performance. Securities firms' analysis that the value of TG-C (formerly known as Invossa) ranges from at least 5 trillion KRW to as much as 12 trillion KRW appears to be influencing the stock price.

As of 9:32 AM on the 21st, Kolon TissueGene is trading at 50,100 KRW, up 4.38% from the previous day.

Korea Investment & Securities analyzed that the value of TG-C (formerly Invossa) could reach 8 trillion KRW and set a target price of 100,000 KRW.

Researcher Wi Haeju from Korea Investment & Securities explained, "Osteoarthritis (OA) has many patients but no approved treatments," adding, "In the United States, at least 19% of adults over 45 suffer from knee OA."

He continued, "Due to the nature of the disease, once cartilage is damaged, it cannot recover, so it inevitably worsens over time," and added, "More than 11 pipelines including TG-C have undergone late-stage clinical trials, but TG-C is the only pipeline that has secured positive clinical results."

He analyzed, "TG-C is expected to obtain FDA approval as a knee OA treatment in 2028 and then expand to a disease-modifying osteoarthritis drug (DMOAD) by 2032," noting, "The Phase 3 clinical trial goals of pain reduction and joint function improvement have already been achieved." He also said, "The likelihood of approval as an OA treatment is high," and "Proving cartilage regeneration effects is key for expanding to DMOAD."

Researcher Wi stated, "Applying analysis methods favorable for demonstrating TG-C's cartilage regeneration effects, increasing patient numbers, and extending observation periods can enhance the chances of success," and predicted, "The long-term follow-up clinical results to be released at the end of next month will heighten expectations for DMOAD approval."

He estimated the value of TG-C under different scenarios. If approved only as an OA treatment, the value is 5 trillion KRW; if expanded to DMOAD after OA approval, the value is 8 trillion KRW. If approvals for both OA treatment and DMOAD are obtained simultaneously, the value is expected to reach 12 trillion KRW.